Genmab A/S
GMAB22.055USD
+0.275+1.26%
Market hours （ET）Quotes delayed by 15 min
1.40BMarket Cap
0.41P/E TTM
More Details of Genmab A/S Company
Genmab A/S is a Denmark-based international biotechnology company. It specializes in the creation and development of antibody therapeutics for the treatment of cancer. The Company is the creator of the approved antibodies: DARZALEX (daratumumab) for the treatment of certain multiple myeloma indications, Kesimpta for the treatment of adults with relapsing forms of multiple sclerosis, TEPEZZA (teprotumumab) for the treatment of thyroid eye disease and FASPRO, for the treatment of adult patients with certain multiple myeloma indications. The first approved Genmab created therapy Arzerra, approved for the treatment of certain chronic lymphocytic leukemia indications, is available in Japan and is also available in other territories via compassionate use or oncology access programs. Genmab develops a broad clinical and pre-clinical product pipeline, and owns four antibody technologies, DuoBody bispecific platform, HexaBody platform, DuoHexaBody platform & HexElect platform.
Company Info
Ticker SymbolGMAB
Company nameGenmab A/S
IPO dateOct 01, 2000
CEODr. Jan G.J. Van De Winkel, Ph.D.
Number of employees2682
Security typeOrdinary Share
Fiscal year-endOct 01
AddressCarl Jacobsens Vej 30
CityVALBY
Stock exchangeOMX Nordic Exchange Copenhagen A/S
CountryDenmark
Postal code2500
Phone4570202728
Websitehttps://www.genmab.com/
Ticker SymbolGMAB
IPO dateOct 01, 2000
CEODr. Jan G.J. Van De Winkel, Ph.D.
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. Tahamtan (Tahi) Ahmadi, M.D., Ph.D.
Dr. Tahamtan (Tahi) Ahmadi, M.D., Ph.D.
Executive Vice President, Chief Medical Officer, Head of Experimental Medicines
Executive Vice President, Chief Medical Officer, Head of Experimental Medicines
--
--
Dr. Judith V. Klimovsky, M.D.
Dr. Judith V. Klimovsky, M.D.
Executive Vice President, Chief Development Officer
Executive Vice President, Chief Development Officer
--
--
Ms. Pernille Lyngvold Erenbjerg
Ms. Pernille Lyngvold Erenbjerg
Independent Deputy Chairman of the Board
Independent Deputy Chairman of the Board
--
--
Mr. Christopher Cozic
Mr. Christopher Cozic
Executive Vice President, Chief People Officer
Executive Vice President, Chief People Officer
--
--
Mr. Martin Schultz
Mr. Martin Schultz
Non-Independent Director, Employee Elected
Non-Independent Director, Employee Elected
--
--
Dr. Anders Gersel Pedersen, M.D., Ph.D.
Dr. Anders Gersel Pedersen, M.D., Ph.D.
Non-Independent Director
Non-Independent Director
--
--
Dr. Paolo Paoletti, M.D.
Dr. Paolo Paoletti, M.D.
Independent Director
Independent Director
--
--
Dr. Jan G.J. Van De Winkel, Ph.D.
Dr. Jan G.J. Van De Winkel, Ph.D.
President, Chief Executive Officer
President, Chief Executive Officer
--
--
Ms. Mijke Zachariasse, Ph.D.
Ms. Mijke Zachariasse, Ph.D.
Non-Independent Director, Employee Elected
Non-Independent Director, Employee Elected
--
--
Ms. Elizabeth A. O'farrell
Ms. Elizabeth A. O'farrell
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Tahamtan (Tahi) Ahmadi, M.D., Ph.D.
Dr. Tahamtan (Tahi) Ahmadi, M.D., Ph.D.
Executive Vice President, Chief Medical Officer, Head of Experimental Medicines
Executive Vice President, Chief Medical Officer, Head of Experimental Medicines
--
--
Dr. Judith V. Klimovsky, M.D.
Dr. Judith V. Klimovsky, M.D.
Executive Vice President, Chief Development Officer
Executive Vice President, Chief Development Officer
--
--
Ms. Pernille Lyngvold Erenbjerg
Ms. Pernille Lyngvold Erenbjerg
Independent Deputy Chairman of the Board
Independent Deputy Chairman of the Board
--
--
Mr. Christopher Cozic
Mr. Christopher Cozic
Executive Vice President, Chief People Officer
Executive Vice President, Chief People Officer
--
--
Mr. Martin Schultz
Mr. Martin Schultz
Non-Independent Director, Employee Elected
Non-Independent Director, Employee Elected
--
--
Dr. Anders Gersel Pedersen, M.D., Ph.D.
Dr. Anders Gersel Pedersen, M.D., Ph.D.
Non-Independent Director
Non-Independent Director
--
--
Revenue Breakdown
Currency: USDUpdated: Sun, Jul 6
Currency: USDUpdated: Sun, Jul 6
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
By BusinessUSD
Name
Revenue
Proportion
Royalties
589.00M
82.38%
Net product sales
75.00M
10.49%
Reimbursement income
23.00M
3.22%
Collaboration revenue
16.00M
2.24%
Milestone payments
12.00M
1.68%
No Data
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Royalties
589.00M
82.38%
Net product sales
75.00M
10.49%
Reimbursement income
23.00M
3.22%
Collaboration revenue
16.00M
2.24%
Milestone payments
12.00M
1.68%
Shareholding Stats
Updated: Sat, May 17
Updated: Sat, May 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
AllianceBernstein L.P.
2.32%
Orbis Investment Management Ltd.
0.90%
Citadel Advisors LLC
0.70%
Two Sigma Investments, LP
0.61%
BlackRock Institutional Trust Company, N.A.
0.47%
Other
95.00%
Shareholders
Shareholders
Proportion
AllianceBernstein L.P.
2.32%
Orbis Investment Management Ltd.
0.90%
Citadel Advisors LLC
0.70%
Two Sigma Investments, LP
0.61%
BlackRock Institutional Trust Company, N.A.
0.47%
Other
95.00%
Shareholder Types
Shareholders
Proportion
Investment Advisor/Hedge Fund
4.27%
Investment Advisor
2.99%
Hedge Fund
2.45%
Research Firm
0.51%
Pension Fund
0.03%
Bank and Trust
0.02%
Venture Capital
0.01%
Other
89.73%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
498
64.99M
10.26%
-6.57M
2025Q1
515
65.99M
10.42%
-5.32M
2024Q4
512
61.76M
9.33%
+621.44K
2024Q3
493
53.46M
8.41%
-4.14M
2024Q2
495
49.90M
7.86%
-6.30M
2024Q1
501
49.04M
7.53%
-7.16M
2023Q4
490
47.86M
7.32%
-6.37M
2023Q3
479
48.54M
7.43%
+204.98K
2023Q2
467
42.76M
6.55%
-5.77M
2023Q1
481
44.22M
6.78%
-6.32M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
AllianceBernstein L.P.
14.73M
2.32%
-210.07K
-1.41%
Mar 31, 2025
Orbis Investment Management Ltd.
5.71M
0.9%
+2.90M
+102.83%
Mar 31, 2025
Citadel Advisors LLC
4.43M
0.7%
+1.33M
+43.16%
Mar 31, 2025
Two Sigma Investments, LP
3.87M
0.61%
+513.60K
+15.29%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
2.95M
0.47%
-433.32K
-12.82%
Mar 31, 2025
Harding Loevner LP
2.88M
0.45%
+637.43K
+28.41%
Mar 31, 2025
Renaissance Technologies LLC
2.26M
0.36%
+336.20K
+17.45%
Mar 31, 2025
Marshall Wace LLP
2.18M
0.34%
+1.06M
+94.38%
Mar 31, 2025
Brandywine Global Investment Management, LLC
1.72M
0.27%
+97.63K
+6.03%
Mar 31, 2025
First Trust Advisors L.P.
1.71M
0.27%
+65.52K
+3.98%
Mar 31, 2025
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
Tema Oncology ETF
3.66%
First Trust NYSE Arca Biotechnology Index Fund
3.45%
WisdomTree BioRevolution Fund
0.99%
iShares Biotechnology ETF
0.87%
First Trust NASDAQ BuyWrite Income ETF
0.2%
ProShares Ultra Nasdaq Biotechnology
0.1%
Invesco Nasdaq Biotechnology ETF
0.1%
Avantis International Equity ETF
0.07%
ActivePassive International Equity ETF
0.07%
Avantis International Large Cap Value ETF
0.05%
View more
Tema Oncology ETF
Proportion3.66%
First Trust NYSE Arca Biotechnology Index Fund
Proportion3.45%
WisdomTree BioRevolution Fund
Proportion0.99%
iShares Biotechnology ETF
Proportion0.87%
First Trust NASDAQ BuyWrite Income ETF
Proportion0.2%
ProShares Ultra Nasdaq Biotechnology
Proportion0.1%
Invesco Nasdaq Biotechnology ETF
Proportion0.1%
Avantis International Equity ETF
Proportion0.07%
ActivePassive International Equity ETF
Proportion0.07%
Avantis International Large Cap Value ETF
Proportion0.05%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
